BRIEF published on 09/03/2026 at 19:20, 1 month 13 days ago Change at the helm of Poxel: Laure-Hélène Mercier appointed President Shareholders Biotechnology Governance Appointment Poxel
BRIEF published on 09/03/2026 at 19:20, 1 month 13 days ago Laure-Hélène Mercier Appointed Chair of Poxel's Board Biotechnology Corporate Governance Board Appointment Poxel Financial Oversight
PRESS RELEASE published on 09/03/2026 at 19:15, 1 month 13 days ago Inside Information / Other news releases Laure-Hélène Mercier appointed as Chair of Poxel's Board of Directors, enhancing governance and financial oversight. Sophie Jacq Lapointe steps down with gratitude. Poxel focuses on metabolic diseases and HCM treatments Governance Metabolic Diseases Poxel Laure-Hélène Mercier HCM
BRIEF published on 07/30/2026 at 21:35, 2 months 17 days ago Poxel Records Positive Turnover amidst Financial Statement Postponement Financial Statements Royalties Poxel TWYMEEG® Sales Debt Valuation
BRIEF published on 07/30/2026 at 21:35, 2 months 17 days ago Poxel: Q2 2026 Results and 2025 Financial Statements Report Revenue TWYMEEG® Poxel Sumitomo Pharma 2025 Accounts
PRESS RELEASE published on 07/30/2026 at 21:30, 2 months 17 days ago Inside Information / Other news releases Poxel publishes Q2 2026 turnover & delays 2025 financial statements release. TWYMEEG(R) net sales up in Japan, reaching 2.9 billion yen; royalty rate to increase Financial Statements Turnover Royalties Poxel TWYMEEG
BRIEF published on 06/10/2026 at 20:18, 4 months 6 days ago Poxel appoints Yves Decadt as its new Chief Executive Officer Strategic Partnerships Biopharmaceutical Continuation Plan Poxel Yves Decadt
BRIEF published on 06/10/2026 at 20:18, 4 months 6 days ago Poxel Appoints Yves Decadt as CEO to Advance Strategic Goals Strategic Partnerships Biopharmaceutical Poxel Imeglimin Yves Decadt
PRESS RELEASE published on 06/10/2026 at 20:13, 4 months 6 days ago Inside Information / Other news releases Poxel appoints Yves Decadt as Chief Executive Officer to accelerate portfolio development and strategic partnerships. Yves Decadt brings over 25 years of international pharmaceutical industry experience Strategic Partnerships Chief Executive Officer Portfolio Development Poxel Yves Decadt
BRIEF published on 03/31/2026 at 13:12, 6 months 16 days ago Poxel sells the PXL770 to Scynexis for a potential value of $196 million Financial Agreement Poxel PXL770 SCYNEXIS Polycystic Kidney Disease
Published on 10/17/2026 at 03:20, 4 hours 48 minutes ago Battery X Metals Highlights Participation at X Takeover 2026, an Electric Vehicle and Emerging Technology Event Held at Tesla's Gigafactory Texas, Providing Exposure to Industry Perspectives and Technology Developments
Published on 10/17/2026 at 03:15, 4 hours 53 minutes ago Vanta Closes Second Tranche of Private Placement Financing and Welcomes Launch of First U.S.-Listed Peptide ETF, Highlighting Growing Recognition of Peptide Industry
Published on 10/16/2026 at 23:35, 8 hours 33 minutes ago Initial Closing of US$3.4 Million Private Placement
Published on 10/16/2026 at 23:30, 8 hours 38 minutes ago NiobiumX Mining Inc. Announces Retraction of Recent Marketing Materials
Published on 10/16/2026 at 23:00, 9 hours 8 minutes ago Grid Announces Adoption of Advance Notice By-Law and Provides Shareholder Meeting Update
Published on 10/16/2026 at 20:08, 11 hours 59 minutes ago EQS-Adhoc: Rath AG // Rath Group reaches agreement with its key financial creditors on the terms of a transformation agreement and launches a transformation programme
Published on 10/16/2026 at 19:20, 12 hours 47 minutes ago Arity to Acquire INRIX, Advancing a Connected Vision for the Future of Transportation
Published on 10/16/2026 at 19:05, 13 hours 3 minutes ago Paris Court Ruling on Discontinued Feature Will Have Minimal Impact on Angelalign Customers
Published on 10/16/2026 at 18:18, 13 hours 49 minutes ago Issue Price of Placing and WRAP Retail Offer
Published on 10/16/2026 at 18:13, 13 hours 54 minutes ago EQS-Adhoc: DHL AG: DHL AG raises full-year 2026 earnings guidance
Published on 10/16/2026 at 18:48, 13 hours 19 minutes ago Disclosure of transactions in own shares from October 12 to October 16, 2026
Published on 10/15/2026 at 18:50, 1 day 13 hours ago September & first 9 months of 2026 traffic figures - Revision of Traffic assumptions for 2026
